Nasus Pharma NSRX
NYSE NSRX
$3.99 +0.17 (+4.45%)
At close: Oct 2, 2026 · 4:00 PM EDT

Nasus Pharma (NSRX) Liabilities from Discontinued Operations (2024 - 2026)

Updated

Nasus Pharma (NSRX) recorded Liabilities from Discontinued Operations of $435,000 in Q2 2026, down 20.5% from $547,000 a year earlier.

Analysis

Nasus Pharma (NSRX) Liabilities from Discontinued Operations (2024 - 2026) Analysis & Trends

At the end of FY2025, Nasus Pharma reported Liabilities from Discontinued Operations of $483,000, down 1.2% from FY2024.

  • Across earlier years, Liabilities from Discontinued Operations came in at $489,000 in FY2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,082.65 Bn 1,051.23 Bn 19.71 Bn
2 Johnson & Johnson 623.68 Bn 542.21 Bn 17.26 Bn
3 AbbVie 459.43 Bn 432.59 Bn 12.70 Bn
4 Merck 354.80 Bn 309.23 Bn 12.21 Bn
5 Novartis Ag 269.16 Bn 225.03 Bn 11.24 Bn
6 Astrazeneca 244.40 Bn 217.97 Bn 12.86 Bn
7 Amgen 220.17 Bn 175.57 Bn 7.24 Bn
8 Gilead Sciences 183.05 Bn 157.16 Bn 6.22 Bn
9 Pfizer 160.27 Bn 107.22 Bn 10.94 Bn
10 Nasus Pharma 34.44 Mn 34.44 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 435,000.00
Dec 31, 2025 483,000.00
Jun 30, 2025 547,000.00
Dec 31, 2024 489,000.00
API Access

Nasus Pharma Liabilities from Discontinued Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-from-discontinued-operations&ticker=NSRX&period=max&api_key=YOUR_API_KEY